0000950170-23-035679.txt : 20230731 0000950170-23-035679.hdr.sgml : 20230731 20230731075844 ACCESSION NUMBER: 0000950170-23-035679 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230727 FILED AS OF DATE: 20230731 DATE AS OF CHANGE: 20230731 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Parker Geoffrey M. CENTRAL INDEX KEY: 0001491874 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39864 FILM NUMBER: 231125063 MAIL ADDRESS: STREET 1: 15 RIORDAN PLACE CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Better Therapeutics, Inc. CENTRAL INDEX KEY: 0001832415 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 548 MARKET ST. #49404 CITY: SAN FRANCISCO STATE: CA ZIP: 94101 BUSINESS PHONE: 415-887-2311 MAIL ADDRESS: STREET 1: 548 MARKET ST. #49404 CITY: SAN FRANCISCO STATE: CA ZIP: 94101 FORMER COMPANY: FORMER CONFORMED NAME: Mountain Crest Acquisition Corp II DATE OF NAME CHANGE: 20201116 4 1 ownership.xml 4 X0508 4 2023-07-27 0001832415 Better Therapeutics, Inc. BTTX 0001491874 Parker Geoffrey M. C/O BETTER THERAPEUTICS, INC. 548 MARKET STREET, #49404 SAN FRANCISCO CA 94104 true false false false false Common Stock 2023-07-27 4 P false 685025 0.7299 A 1028055 D Common Stock 53333 I By Parker Trust On July 25, 2023, the Issuer entered into a Securities Purchase Agreement with certain investors (the "PIPE Investors") in a private placement offering, pursuant to which the PIPE Investors agreed to purchase shares of Issuer common stock for $0.7299 per share. As one of the PIPE Investors, the Reporting Person acquired 685,025 shares of Issuer common stock on July 27, 2023 for $0.7299 per share. These shares are owned directly by the Geoffrey M. Parker and Jill G. Parker Rev Trust dtd 1/27/00 (the "Parker Trust"), and indirectly by the Reporting Person and his spouse, Jill G. Parker, as trustees of the Parker Trust. /s/ Mark Heinen, Attorney-in-Fact 2023-07-31